Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial (Q38735563)

From Wikidata

Jump to navigation Jump to search

scientific article published on 31 March 2017

Language	Label	Description	Also known as
English	Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial	scientific article published on 31 March 2017

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

3 July 2019

http://europepmc.org/abstract/PMC/6387686

Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial (English)

1 reference

Europe PubMed Central

PMC publication ID

3 July 2019

http://europepmc.org/abstract/PMC/6387686

17

object named as

Jeffrey Schlom

1 reference

Europe PubMed Central

PMC publication ID

3 July 2019

http://europepmc.org/abstract/PMC/6387686

James L. Gulley

18

object named as

James L Gulley

1 reference

Europe PubMed Central

PMC publication ID

3 July 2019

http://europepmc.org/abstract/PMC/6387686

author name string

Christopher R Heery

1

1 reference

Europe PubMed Central

PMC publication ID

3 July 2019

http://europepmc.org/abstract/PMC/6387686

Geraldine O'Sullivan-Coyne

2

1 reference

Europe PubMed Central

PMC publication ID

3 July 2019

http://europepmc.org/abstract/PMC/6387686

Ravi A Madan

3

1 reference

Europe PubMed Central

PMC publication ID

3 July 2019

http://europepmc.org/abstract/PMC/6387686

Lisa Cordes

4

1 reference

Europe PubMed Central

PMC publication ID

3 July 2019

http://europepmc.org/abstract/PMC/6387686

Arun Rajan

5

1 reference

Europe PubMed Central

PMC publication ID

3 July 2019

http://europepmc.org/abstract/PMC/6387686

Myrna Rauckhorst

6

1 reference

Europe PubMed Central

PMC publication ID

3 July 2019

http://europepmc.org/abstract/PMC/6387686

Elizabeth Lamping

7

1 reference

Europe PubMed Central

PMC publication ID

3 July 2019

http://europepmc.org/abstract/PMC/6387686

Israel Oyelakin

8

1 reference

Europe PubMed Central

PMC publication ID

3 July 2019

http://europepmc.org/abstract/PMC/6387686

Jennifer L Marté

9

1 reference

Europe PubMed Central

PMC publication ID

3 July 2019

http://europepmc.org/abstract/PMC/6387686

Lauren M Lepone

10

1 reference

Europe PubMed Central

PMC publication ID

3 July 2019

http://europepmc.org/abstract/PMC/6387686

Renee N Donahue

11

1 reference

Europe PubMed Central

PMC publication ID

3 July 2019

http://europepmc.org/abstract/PMC/6387686

Italia Grenga

12

1 reference

Europe PubMed Central

PMC publication ID

3 July 2019

http://europepmc.org/abstract/PMC/6387686

Jean-Marie Cuillerot

13

1 reference

Europe PubMed Central

PMC publication ID

3 July 2019

http://europepmc.org/abstract/PMC/6387686

Berend Neuteboom

14

1 reference

Europe PubMed Central

PMC publication ID

3 July 2019

http://europepmc.org/abstract/PMC/6387686

Anja von Heydebreck

15

1 reference

Europe PubMed Central

PMC publication ID

3 July 2019

http://europepmc.org/abstract/PMC/6387686

Kevin Chin

16

1 reference

Europe PubMed Central

PMC publication ID

3 July 2019

http://europepmc.org/abstract/PMC/6387686

publication date

31 March 2017

1 reference

Europe PubMed Central

PMC publication ID

3 July 2019

http://europepmc.org/abstract/PMC/6387686

Lancet Oncology Commission

1 reference

Europe PubMed Central

PMC publication ID

3 July 2019

http://europepmc.org/abstract/PMC/6387686

18

1 reference

Europe PubMed Central

PMC publication ID

3 July 2019

http://europepmc.org/abstract/PMC/6387686

5

1 reference

Europe PubMed Central

PMC publication ID

3 July 2019

http://europepmc.org/abstract/PMC/6387686

587-598

1 reference

Europe PubMed Central

PMC publication ID

3 July 2019

http://europepmc.org/abstract/PMC/6387686

Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930239-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Nivolumab in previously untreated melanoma without BRAF mutation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930239-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Pembrolizumab versus Ipilimumab in Advanced Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930239-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930239-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930239-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Pembrolizumab for the treatment of non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930239-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930239-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930239-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930239-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930239-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Malignant Mesothelioma Effusions Are Infiltrated by CD3+ T Cells Highly Expressing PD-L1 and the PD-L1+ Tumor Cells within These Effusions Are Susceptible to ADCC by the Anti-PD-L1 Antibody Avelumab

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930239-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930239-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Systemic Immunotherapy of Non-Muscle Invasive Mouse Bladder Cancer with Avelumab, an Anti-PD-L1 Immune Checkpoint Inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930239-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Analyses of 123 Peripheral Human Immune Cell Subsets: Defining Differences with Age and between Healthy Donors and Cancer Patients Not Detected in Analysis of Standard Immune Cell Types.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930239-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Acute autoimmune hepatitis, myositis, and myasthenic crisis in a patient with thymoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930239-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Thymic carcinoma associated with paraneoplastic polymyositis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930239-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Multiorgan autoimmune manifestations associated with thymoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930239-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Thymoma-associated paraneoplastic polymyositis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930239-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A fully human IgG1 anti-PD-L1 MAb in an in vitro assay enhances antigen-specific T-cell responses

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930239-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930239-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930239-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical immunotoxicity of therapeutic proteins

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930239-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930239-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Acute effects of alemtuzumab infusion in patients with active relapsing-remitting MS.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930239-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930239-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930239-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930239-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of charge on antibody tissue distribution and pharmacokinetics.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930239-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Framework selection can influence pharmacokinetics of a humanized therapeutic antibody through differences in molecule charge

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930239-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/28373007

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1016/S1470-2045(17)30239-5

1 reference

Europe PubMed Central

PMC publication ID

3 July 2019

http://europepmc.org/abstract/PMC/6387686

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

3 July 2019

http://europepmc.org/abstract/PMC/6387686

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

3 July 2019

http://europepmc.org/abstract/PMC/6387686

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38735563&oldid=1781621539"